Drug intelligence / Profile preview

Panblok H7

Development stage: Phase 2
Lead developer: Sanofi Pasteur
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Panblok H7 is a recombinant hemagglutinin (rHA) influenza vaccine developed for protection against H7N9 influenza virus. The vaccine contains recombinant H7 hemagglutinin derived from A/Guangdong/17SF003/2016 (H7N9) influenza virus strain. Clinical trials have tested the vaccine both with and without adjuvants (AS03 or MF59), as H7 hemagglutinin is known to be poorly immunogenic. When adjuvanted, the vaccine has shown improved immunogenicity and safety profiles.

Brand names: Panblok H7
Other names: Recombinant H7 Hemagglutinin Influenza Vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on Panblok H7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panblok H7.

Explore the full profile